AGA Management of Mild-to-Moderate Ulcerative Colitis Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the American Gastroenterological Association.

Document Overview

Document Title: Management of Mild-to-Moderate Ulcerative Colitis

Authoring Society: American Gastroenterological Association

Document Publication Date: Feb 1, 2019

Page Last Reviewed/Updated: Feb 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: www.gastrojournal.org/article/S0016-5085(18)35407-6/fulltext

Source Citation: Cynthia W Ko, Siddharth Singh, Joseph D. Feuerstein, Corinna Falck-Ytter, Yngve Falck-Ytter, and Raymond K. Cross on behalf of the American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Management of Mild-Moderate Ulcerative Colitis

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Document Objectives: This guideline addresses the medical management of patients with mild–moderate UC, focusing on use of both oral and topical 5-ASA medications, rectal corticosteroids, and oral budesonide.

Scope: Management

Diseases/Conditions (MeSH): D003093 - Colitis, Ulcerative

Keywords: IBD, UC, inflammatory bowel disease, ulcerative colitis

Target Patient Population: Patients with mild-to-moderate ulcerative colitis (UC)

Health Care Settings: Ambulatory

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resource: Technical Review

Number of Source Documents: 170

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No